Cytokinetics (NASDAQ:CYTK) Issues Earnings Results, Beats Estimates By $0.07 EPS

Posted by Francis Steltz on Nov 4th, 2026

Cytokinetics (NASDAQ:CYTK – Get Free Report) posted its earnings results on Wednesday. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.44) by $0.07, Zacks reports. The business had revenue of $47.56 million for the quarter, compared to analyst estimates of $41.88 million. During the same quarter in the prior year, the firm earned ($2.55) earnings per share. The company’s revenue for the quarter was up 2356.5% on a year-over-year basis.

Here are the key takeaways from Cytokinetics’ conference call:

MYQORZO generated $44.5 million in Q3 net product revenue, up 76% sequentially. Prescribers and dispensed patients grew, while new-to-brand share approached 45%; the company is targeting more than 50% by year-end.
Cytokinetics plans to submit an aficamten supplemental NDA for symptomatic non-obstructive HCM this quarter, following positive Phase 3 ACACIA-HCM results. The company is also preparing for a potential 2027 launch, though approval and the eventual label remain uncertain.
MYQORZO’s international rollout is progressing, with Germany showing early traction and a U.K. launch expected this quarter. The company expects launches in additional countries in 2027, while noting broader European revenue may take until 2028–2029 to build meaningfully.
The company ended Q3 with approximately $1.6 billion in cash and investments and reaffirmed 2026 combined R&D and SG&A expense guidance of $860 million–$890 million. Quarterly SG&A increased to $113.1 million as commercial launch costs rose, while the company reported a $190.1 million net loss.

Cytokinetics Price Performance

NASDAQ CYTK traded up $1.29 during trading hours on Wednesday, hitting $63.60. 2,916,652 shares of the company’s stock traded hands, compared to its average volume of 1,525,180. Cytokinetics has a 52-week low of $58.05 and a 52-week high of $88.31. The company has a market capitalization of $7.91 billion, a PE ratio of -8.81 and a beta of 0.45. The firm’s 50-day moving average is $66.63 and its 200-day moving average is $70.05.

Insider Buying and Selling at Cytokinetics

In other news, Director B. Parshall sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total transaction of $357,400.00. Following the transaction, the director owned 10,784 shares of the company’s stock, valued at approximately $770,840.32. The trade was a 31.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 10,000 shares of Cytokinetics stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $70.24, for a total transaction of $702,400.00. Following the transaction, the executive vice president directly owned 58,555 shares in the company, valued at $4,112,903.20. This trade represents a 14.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 180,926 shares of company stock valued at $12,510,340. Company insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CYTK. Barclays raised their price objective on shares of Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. JPMorgan Chase & Co. boosted their target price on shares of Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. UBS Group reissued a “buy” rating and set a $104.00 price target on shares of Cytokinetics in a report on Wednesday, October 14th. Wall Street Zen downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a report on Tuesday, October 20th. Finally, Needham & Company LLC lifted their price objective on shares of Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a report on Friday, August 7th. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Cytokinetics has a consensus rating of “Moderate Buy” and an average target price of $105.44.

View Our Latest Report on Cytokinetics

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

Positive Sentiment: Cytokinetics reported a third-quarter loss of $1.37 per share, better than analysts’ expected loss of $1.44, and revenue of $47.56 million versus estimates of $41.88 million. Revenue rose 2,356.5% year over year, and the per-share loss narrowed from $2.55 in the year-ago quarter. Earnings report
Neutral Sentiment: CEO Robert Blum and EVP Fady Malik sold shares under pre-arranged Rule 10b5-1 trading plans. The sales totaled 7,500 and 3,500 shares, respectively; both executives retained substantial holdings, which may reduce the significance of the transactions. Insider sale report

About Cytokinetics

(Get Free Report)

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.